102 WOODMONT BLVD, NASHVILLE, TN
Closes Acquisition of TYRVAYA®
Randall Pollard Departs as Chief Accounting Officer; Andrew Boll Appointed
Reports Strong Second Quarter 2026 Revenue and Outlines Path to $250 Million Revenue Quarter by End of 2027
Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Election of Directors at Harrow, Inc. Annual Meeting; Results Announced
Investor Presentation
Announces First Quarter 2026 Financial Results
Harrow, Inc. Enters $50 Million Purchase Agreement for Senior Notes
Q2
Q1
FY 2025
Q3
FY 2024
Notice of Late Filing for Annual Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Certificate
Registration of Securities
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Prospectus filed pursuant to Rule 305(b)(2)
Correspondence
Submission Upload